A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2006
10/24/2006	CA2275587C Injectable depot gel composition and method of preparing the composition
10/24/2006	CA2274183C Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
10/24/2006	CA2264929C Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
10/24/2006	CA2264598C 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives
10/24/2006	CA2261848C Cell adhesion inhibitors
10/24/2006	CA2259031C Androgen receptor modulator compounds and methods
10/24/2006	CA2257121C Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
10/24/2006	CA2253811C Taste masked liquid suspensions
10/24/2006	CA2252717C Colchicine-skeleton compounds, their use as medicaments and compositions containing them
10/24/2006	CA2249402C Benzopyran derivatives having leukotriene-antagonistic action
10/24/2006	CA2245383C Famciclovir monohydrate
10/24/2006	CA2237650C Benzamidoxime prodrugs as antipneumocystic agents
10/24/2006	CA2227711C Thioctic acid metabolites and methods of use thereof
10/24/2006	CA2222517C Agents for use against parasitic protozoa
10/24/2006	CA2220682C Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions
10/24/2006	CA2208199C Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
10/24/2006	CA2205315C Fluorinated vitamin d3 analogs
10/24/2006	CA2195663C Dihydrobenzofuranes
10/24/2006	CA2168877C Agent for curing neuronal diseases
10/24/2006	CA2168023C Vasoconstrictive substituted aryloxyalkyl diamines
10/24/2006	CA2167584C Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
10/24/2006	CA2158400C Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenes
10/24/2006	CA2152089C Asymmetric process for preparing florfenicol, thiamphenicol, chloramphenicol, and oxazoline intermediates
10/24/2006	CA2072978C Process for the heterotrophic production of products with high concentrations of omega-3 highly unsaturated fatty acids
10/21/2006	CA2504643A1 Methods of upregulating the heme oxygenase/carbon monoxide (ho/co) pathway
10/19/2006	WO2006110924A2 Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration
10/19/2006	WO2006110918A1 Pyrrole compounds and uses thereof
10/19/2006	WO2006110917A2 Spiro-oxindole compounds and their uses as therapeutic agents
10/19/2006	WO2006110816A2 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
10/19/2006	WO2006110815A1 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
10/19/2006	WO2006110814A2 Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
10/19/2006	WO2006110811A1 Nanoparticulate quinazoline derivative formulations
10/19/2006	WO2006110810A2 Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
10/19/2006	WO2006110809A2 Nanoparticulate lipase inhibitor formulations
10/19/2006	WO2006110777A1 Method of treating or preventing bone deterioration or osteoporosis
10/19/2006	WO2006110775A2 Antisense oligonucleotides for modifying expression of acc1 and acc2 and for controlling metabolic disorders
10/19/2006	WO2006110726A2 Dosage formulations and methods of treatment and prevention
10/19/2006	WO2006110724A2 Method of treating schizophrenia prodrome
10/19/2006	WO2006110699A1 Quaternary ammonium halides for treatment of infectious conditions
10/19/2006	WO2006110683A1 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
10/19/2006	WO2006110668A1 Compounds which inhibit beta-secretase activity and methods of use thereof
10/19/2006	WO2006110656A2 Compounds, compositions and methods for the treatment of viral infections and other medical disorders
10/19/2006	WO2006110655A2 Compounds, compositions and methods for the treatment of poxvirus infections
10/19/2006	WO2006110654A1 Spiroheterocyclic compounds and their uses as therapeutic agents
10/19/2006	WO2006110642A2 Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
10/19/2006	WO2006110638A2 Inhibitors of akt activity
10/19/2006	WO2006110607A2 Methods for treating infectious disease exacerbated asthma
10/19/2006	WO2006110601A2 The genetic risk assessment in heart failure: impact of the genetic variation of nos3
10/19/2006	WO2006110588A2 Methods for treating mild cognitive impairment
10/19/2006	WO2006110580A2 Methods for treating anxiety related disorders
10/19/2006	WO2006110557A2 Methods for the treatment of substance abuse and dependence
10/19/2006	WO2006110534A2 A process for preparing a crystalline form of halobetasol propionate
10/19/2006	WO2006110531A2 Acyl homoserine lactones for inhibition of cell growth
10/19/2006	WO2006110516A1 Acylhydrazide p2x7 antagonists and uses thereof
10/19/2006	WO2006110491A2 Complementary compositions to reduce blood glucose levels and treat diabetes
10/19/2006	WO2006110490A2 Agents and methods for osteogenic oxysterols inhibition of oxidative stress on osteogenic cellular differentiation
10/19/2006	WO2006110483A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
10/19/2006	WO2006110477A2 Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus
10/19/2006	WO2006110390A1 Mitotic kinesin inhibitors
10/19/2006	WO2006110366A1 Medical devices and methods for producing the same
10/19/2006	WO2006110299A1 3,3'-diindolylmethane compositions inhibit angiogenesis
10/19/2006	WO2006110298A2 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
10/19/2006	WO2006110187A2 Methods and compositions for the treatment of anxiety disorders
10/19/2006	WO2006110175A2 Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
10/19/2006	WO2006110173A2 Novel compounds
10/19/2006	WO2006110157A2 Nucleoside phosphonate conjugates as anti hiv agents
10/19/2006	WO2006110155A1 Solid forms of linezolid and processes for preparation thereof
10/19/2006	WO2006110120A1 Agent for treating a man erectile dysfunction
10/19/2006	WO2006110119A1 Antineoplastic preparation
10/19/2006	WO2006110118A1 Cytoprotection preparation
10/19/2006	WO2006109881A1 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
10/19/2006	WO2006109876A1 Agent for treating involuntary movement
10/19/2006	WO2006109867A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVE OR MEDICALLY ACCEPTABLE SALT THEREOF
10/19/2006	WO2006109846A1 Triazole derivative and the use thereof
10/19/2006	WO2006109823A1 2-thioethenyl carbapenem derivative
10/19/2006	WO2006109817A1 1,4-substituted piperazine derivative
10/19/2006	WO2006109811A1 Process for producing an aminomethyl thiazole compound
10/19/2006	WO2006109762A1 Novel process for producing ramosetron or its salt
10/19/2006	WO2006109737A1 Pranlukast hydrate-containing preparation having relieved bitterness
10/19/2006	WO2006109729A1 Pyridylmethylsulfone derivative
10/19/2006	WO2006109680A1 Use of 3,5-diphenylpyrazole analogue as anti-tumor agent
10/19/2006	WO2006109671A1 Crystals of morphinan derivative and process for producing the same
10/19/2006	WO2006109642A1 Pharmaceutical composition and method using antifungal agent in combination
10/19/2006	WO2006109635A1 Intestinal absorptive anti-tumor agent
10/19/2006	WO2006109633A1 Substituted indole compound
10/19/2006	WO2006109344A2 Composition to be used for the treatment of parodontal pathologies
10/19/2006	WO2006109323A1 Preparation of [2-methyl-5-phenyl-3-(piperazin-1-ylmethyl)] pyrrole derivatives
10/19/2006	WO2006109318A1 Novel polymorph of 3-hydroxy-3-(3’-sulfamyl-4’-chlorophenyl)phthalimidine
10/19/2006	WO2006109190A1 Tetracyclic monoamine reuptake inhibitors for treatment of cns diseases and disorders
10/19/2006	WO2006109183A1 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
10/19/2006	WO2006109177A1 Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
10/19/2006	WO2006109175A2 Solid dosage form of an antidiabetic drug
10/19/2006	WO2006109170A2 Combination therapy for treatment of cardiovascular diseases and related conditions
10/19/2006	WO2006109164A2 A method for preventing, delaying or reverting abnormal amyloid deposition
10/19/2006	WO2006109156A1 Oxazolidinone derivatives as antimicrobials
10/19/2006	WO2006109147A1 Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
10/19/2006	WO2006109092A1 Conjugate comprising p21 protein for the treatment of cancer
10/19/2006	WO2006109091A2 Sensitisation of cancer cells to dna replication inhibitors
10/19/2006	WO2006109085A1 Hydroxybenzamide derivatives and their use as inhibitors of hsp90
10/19/2006	WO2006109084A1 Dna-pk inhibitors

1 ... 4041 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4052 4053 4054 4055 4056 4057 4058 4059 4060 4061 ... 7860